Capital Advisors Ltd’s AbbVie ABBV Stock Holding History

Capital Advisors Ltd’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	4,023 -526	-12%	-$113K	0.1%	127
2026 Q1	$989K	Buy	4,549 +89	+2%	+$19.7K	0.11%	122
2025 Q4	$1.02M	Buy	4,460 +35	+0.8%	+$7.97K	0.11%	114
2025 Q3	$1.02M	Buy	4,425 +30	+0.7%	+$6.11K	0.12%	108
2025 Q2	$816K	Buy	4,395 +51	+1%	+$9.48K	0.1%	119
2025 Q1	$910K	Buy	4,344 +384	+10%	+$74.7K	0.12%	105
2024 Q4	$704K	Buy	3,960 +41	+1%	+$7.54K	0.09%	128
2024 Q3	$774K	Sell	3,919 -534	-12%	-$99.7K	0.1%	119
2024 Q2	$764K	Buy	4,453 +55	+1%	+$9.11K	0.1%	120
2024 Q1	$801K	Buy	4,398 +128	+3%	+$22.1K	0.1%	117
2023 Q4	$662K	Sell	4,270 -79	-2%	-$11.5K	0.09%	121
2023 Q3	$648K	Sell	4,349 -132	-3%	-$19.4K	0.1%	121
2023 Q2	$604K	Buy	4,481 +103	+2%	+$15.1K	0.09%	130
2023 Q1	$698K	Sell	4,378 -630	-13%	-$96.3K	0.11%	104
2022 Q4	$701K	Buy	5,008 +832	+20%	+$128K	0.12%	107
2022 Q3	$560K	Buy	4,176 +132	+3%	+$18.9K	0.11%	114
2022 Q2	$619K	Buy	4,044 +1	+0%	+$153	0.12%	109
2022 Q1	$655K	Buy	4,043 +525	+15%	+$76.3K	0.11%	111
2021 Q4	$476K	Buy	3,518 +660	+23%	+$78K	0.08%	140
2021 Q3	$308K	Buy	2,858 +1,288	+82%	+$147K	0.06%	161
2021 Q2	$177K	Buy	1,570 +2	+0.1%	+$225	0.03%	219
2021 Q1	$170K	Buy	1,568 +1	+0.1%	+$107	0.03%	196
2020 Q4	$168K	Buy	1,567 +1	+0.1%	+$96	0.04%	190
2020 Q3	$137K	Buy	1,566 +2	+0.1%	+$188	0.03%	193
2020 Q2	$154K	Buy	1,564 +1	+0.1%	+$88	0.04%	177
2020 Q1	$119K	Buy	1,563 +97	+7%	+$8.26K	0.04%	188
2019 Q4	$130K	Buy	1,466 +1	+0.1%	+$83	0.03%	185
2019 Q3	$111K	Buy	1,465 +2	+0.1%	+$137	0.03%	191
2019 Q2	$106K	Buy	1,463 +401	+38%	+$31.5K	0.03%	203
2019 Q1	$86K	Buy	1,062 +2	+0.2%	+$164	0.02%	232
2018 Q4	$98K	Buy	1,060 +1	+0.1%	+$88	0.03%	209
2018 Q3	$100K	Buy	1,059 +1	+0.1%	+$95	0.03%	221
2018 Q2	$98K	Buy	1,058 +1	+0.1%	+$98	0.03%	182
2018 Q1	$100K	Hold	1,057	–	–	0.03%	177
2017 Q4	$102K	Buy	1,057 +1	+0.1%	+$94	0.03%	174
2017 Q3	$94K	Buy	1,056 +100	+10%	+$7.61K	0.03%	175
2017 Q2	$69K	Hold	956	–	–	0.03%	189
2017 Q1	$62K	Hold	956	–	–	0.02%	181
2016 Q4	$60K	Hold	956	–	–	0.02%	178
2016 Q3	$60K	Hold	956	–	–	0.03%	174
2016 Q2	$59K	Hold	956	–	–	0.03%	171
2016 Q1	$55K	Hold	956	–	–	0.03%	173
2015 Q4	$57K	Hold	956	–	–	0.03%	169
2015 Q3	$52K	Sell	956 -66	-6%	-$4.3K	0.03%	170
2015 Q2	$69K	Hold	1,022	–	–	0.04%	164
2015 Q1	$60K	Hold	1,022	–	–	0.03%	166
2014 Q4	$67K	Hold	1,022	–	–	0.04%	154
2014 Q3	$59K	Hold	1,022	–	–	0.03%	164
2014 Q2	$58K	Hold	1,022	–	–	0.03%	170
2014 Q1	$53K	Hold	1,022	–	–	0.03%	172
2013 Q4	$54K	Buy	+1,022	New	+$50.2K	0.04%	141

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Advisors Ltd's ABBV Position: Q2 2026 in Review

Capital Advisors Ltd reduced its AbbVie (ABBV) stake by 12% in Q2 2026, selling an estimated $113K and leaving 4,023 shares worth $1.01M. The position accounts for 0.1% of the portfolio, ranked #127.

Capital Advisors Ltd first reported a position in ABBV in Q4 2013 and has held it in 51 quarters since. The position peaked at $1.02M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Capital Advisors Ltd held 4,023 shares of AbbVie worth $1.01M as of Q2 2026.
Capital Advisors Ltd sold 526 AbbVie shares in Q2 2026, an estimated $113K.
AbbVie made up 0.1% of Capital Advisors Ltd's portfolio in Q2 2026, its #127 holding.
Capital Advisors Ltd first reported a position in AbbVie in Q4 2013 and has held it in 51 quarters since.
Capital Advisors Ltd's AbbVie position peaked at $1.02M in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.